Enlightening the immune mechanism of the abscopal effect in a murine HCC model and overcoming the late resistance with anti PD-L1.

[1]  D. Kuang,et al.  The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. , 2019, The Journal of clinical investigation.

[2]  H. Park,et al.  Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma , 2019, World journal of gastroenterology.

[3]  A. Shamseddine,et al.  The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors , 2019, Journal of oncology.

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  Jinming Yu,et al.  Abscopal effect of radiotherapy combined with immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[6]  S. Demaria,et al.  Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. , 2018, Trends in immunology.

[7]  J. Hesser,et al.  Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.

[8]  S. Demaria,et al.  Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers , 2017, Clinical Cancer Research.

[9]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[10]  S. Friedman,et al.  Programmed cell death‐1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  J. Seong,et al.  Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model , 2017, Oncotarget.

[12]  Freeman,et al.  PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity , 2017, The Journal of experimental medicine.

[13]  H. McArthur,et al.  The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer? , 2017, Current Breast Cancer Reports.

[14]  Joël Castelli,et al.  The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. , 2017, Critical reviews in oncology/hematology.

[15]  Lidia Strigari,et al.  A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? , 2017, PloS one.

[16]  S. Demaria,et al.  Current clinical trials testing the combination of immunotherapy with radiotherapy , 2016, Journal of Immunotherapy for Cancer.

[17]  Lipika Goyal,et al.  Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Park,et al.  Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. , 2016, World journal of gastroenterology.

[19]  H. Shan,et al.  Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983–2012 , 2016, Oncotarget.

[20]  L. Que,et al.  A Protocol for the Comprehensive Flow Cytometric Analysis of Immune Cells in Normal and Inflamed Murine Non-Lymphoid Tissues , 2016, PloS one.

[21]  Tao-Tao Liu,et al.  Hepatocellular Carcinoma Cells Induce Regulatory T Cells and Lead to Poor Prognosis via Production of Transforming Growth Factor-β1 , 2016, Cellular Physiology and Biochemistry.

[22]  Kevin J. Harrington,et al.  The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence , 2015, Nature Reviews Cancer.

[23]  A. Salama,et al.  Oncotargets and Therapy Dovepress Clinical Applications of Pd-1-based Therapy: a Focus on Pembrolizumab (mk-3475) in the Management of Melanoma and Other Tumor Types , 2022 .

[24]  Sean S. Park,et al.  PD-1 Restrains Radiotherapy-Induced Abscopal Effect , 2015, Cancer Immunology Research.

[25]  C. Drake,et al.  Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen , 2014, Cancer Immunology Research.

[26]  S. Demaria,et al.  Combinations of Immunotherapy and Radiation in Cancer Therapy , 2014, Front. Oncol..

[27]  I. Stratford,et al.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.

[28]  P. Ascierto,et al.  Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy , 2014, Oncoimmunology.

[29]  S. Demaria,et al.  Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death , 2014, Oncoimmunology.

[30]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[31]  Zahra Kassam,et al.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Swetter,et al.  A systemic complete response of metastatic melanoma to local radiation and immunotherapy. , 2012, Translational oncology.

[33]  C. Porta,et al.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. , 2012, Journal of hepatology.

[34]  Wenxiu Zhao,et al.  The role of hepatic stellate cells in the regulation of T-cell function and the promotion of hepatocellular carcinoma , 2012, International journal of oncology.

[35]  S. Knox,et al.  Abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[36]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[37]  H. Shirato,et al.  Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. , 2010, Cancer research.

[38]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[39]  G. Lockwood,et al.  Phase I study of individualized stereotactic body radiotherapy of liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Kawashima,et al.  Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade , 2009, Clinical Cancer Research.

[41]  T. Heidmann,et al.  Trex1 Prevents Cell-Intrinsic Initiation of Autoimmunity , 2008, Cell.

[42]  J. Aguirre-Ghiso,et al.  Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.

[43]  W. Shi,et al.  Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. , 2006, Anticancer research.

[44]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  Mole Rh.  Whole body irradiation; radiobiology or medicine? , 1953 .

[46]  T. Tiganis,et al.  Isolation and Characterization of Mouse Intrahepatic Lymphocytes by Flow Cytometry. , 2018, Methods in molecular biology.

[47]  P. Venkat,et al.  Systematic review of case reports on the abscopal effect. , 2016, Current problems in cancer.